This is the second article in LuTra Studio’s ADC series, written for readers without prior ADC expertise who want to understand ADC evolution—specifically, why antibody–drug conjugates experienced widespread failures in the 2000s but emerged as one of the most important oncology platforms after 2020. Rather than starting with definitions, this article traces the historical failures, engineering corrections, and strategic shifts that shaped modern ADC development across differ